{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T14:01:09Z","timestamp":1780149669942,"version":"3.54.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) have shown significant cardiorenal benefits in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the impact of GLP\u20101 RAs on cardiorenal outcomes in kidney transplant recipients (KTRs) remains unclear. This study aims to assess the effect of GLP\u20101 RA therapy on proteinuria and metabolic parameters in KTRs, with and without T2DM, 12\u2009months following GLP\u20101 RA initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single\u2010center, retrospective study was conducted to evaluate the safety and efficacy of GLP\u20101 RAs in adult KTRs from June 1, 2022 to December 31, 2023. Primary outcomes were changes in urine protein\u2010creatinine ratio (UPCR) and urine albumin\u2010to\u2010creatinine ratio (UACR) at 1, 3, 6, and 12 months after initiation of GLP\u20101 RAs. Secondary outcomes assessed changes in estimated glomerular filtration (eGFR), body mass index (BMI), and hemoglobin A1c (A1C). Safety outcomes included cardiovascular hospitalizations, acute kidney injury, pancreatitis, and biopsy\u2010proven rejection within 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty KTRs received GLP\u20101 RA therapy with a mean time to initiation of 4.3\u2009months post\u2010transplant, and the majority of patients had T2DM (87.5%). Baseline UPCR and UACR were 0.86 and 669\u2009mg\/g, respectively. UPCR at 1, 3, and 6 months post\u2010initiation was 0.38\u2009g\/g, 0.37\u2009g\/g, and 0.30\u2009g\/g, respectively. UACR at 1, 3, and 6 months post\u2010initiation was 313\u2009mg\/g, 285\u2009mg\/g, and 234\u2009mg\/g, respectively. A 55% decrease from baseline in UPCR and UACR was observed at 1\u2009month (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.070) and a 50% decrease from baseline was observed at 12\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.058), achieving UPCR of 0.43\u2009g\/g and UACR of 320\u2009mg\/g. A1C, eGFR, and BMI remained stable. Minimal safety events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP\u20101 RAs demonstrated clinically significant improvements in proteinuria as early as 1 month post\u2010initiation in KTRs. Proteinuria significantly improved from severely increased to moderately increased at 6\u2009months following GLP\u20101 RAs, with good tolerability. GLP\u20101 RAs may offer renal benefits in KTRs with T2DM without compromising allograft function. Future studies should include closer monitoring of KTRs on immunosuppression with high gastrointestinal adverse effect profiles, and larger studies are needed to assess the long\u2010term impact of GLP\u20101 RAs in KTRs irrespective of T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70123","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:42:17Z","timestamp":1773056537000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Glucagon\u2010Like Peptide\u20101 Receptor Agonists on Proteinuria in Kidney Transplant Recipients"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2180-3037","authenticated-orcid":false,"given":"Stephanie","family":"Shabanowitz","sequence":"first","affiliation":[{"name":"UNC Medical Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9367-7983","authenticated-orcid":false,"given":"Ryan","family":"Clark","sequence":"additional","affiliation":[{"name":"UNC Eshelman School of Pharmacy  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9020-1307","authenticated-orcid":false,"given":"Rachel Bassett","family":"Allen","sequence":"additional","affiliation":[{"name":"UNC Medical Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4309-7896","authenticated-orcid":false,"given":"Mary","family":"Chandran","sequence":"additional","affiliation":[{"name":"UNC Medical Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-205X","authenticated-orcid":false,"given":"Anita","family":"Yang","sequence":"additional","affiliation":[{"name":"UNC Medical Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010020\u201002339\u20109"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1594"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019\u20100195"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2024.1336896"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc\u20102020\u2010001962"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14922"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2011.03.002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3275\/8367"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19\u20102316"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17\u2010S011"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000971"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100343"},{"key":"e_1_2_9_16_1","unstructured":"\u201cClinical Relevance of Postoperative Proteinuria for Prediction of Early Renal Outcomes After Kidney Transplantation \u2013 PubMed \u201daccessed December 16 2024 https:\/\/pubmed\u2010ncbi\u2010nlm\u2010nih\u2010gov.libproxy.lib.unc.edu\/35977905\/."},{"key":"e_1_2_9_17_1","unstructured":"\u201cProteinuria in Kidney Transplant Recipients: Prevalence Prognosis and Evidence\u2010Based Management \u2013 PubMed \u201daccessed December 16 2024 https:\/\/pubmed\u2010ncbi\u2010nlm\u2010nih\u2010gov.libproxy.lib.unc.edu\/19726115\/."},{"key":"e_1_2_9_18_1","unstructured":"\u201cUrine Albumin Creatinine Ratio May Predict Graft Function After Kidney Transplant \u2013 PubMed \u201daccessed December 16 2024 https:\/\/pubmed\u2010ncbi\u2010nlm\u2010nih\u2010gov.libproxy.lib.unc.edu\/31076148\/."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u2010S002"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019060605"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003015\u20105"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.029"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20106143.2006.01361.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.2060"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050707"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.70123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T13:13:30Z","timestamp":1780146810000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/phar.70123"],"URL":"https:\/\/doi.org\/10.1002\/phar.70123","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70123"}}